Cyclacel Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cyclacel Pharmaceuticals generated cash of -$16,111,999, which is more than the previous year. Cash used in financing activities reached the amount of $848,000 last year. Net change in cash is therefore -$14,967,000.
Cash Flow
| 2014 | -18.70M | 75K | 12.2M |
|---|---|---|---|
| 2015 | -14.46M | 62K | 10.86M |
| 2016 | -10.07M | 9K | 6.59M |
| 2017 | -7.48M | -13K | 14.74M |
| 2018 | -6.70M | -39K | 429K |
| 2019 | -9.44M | 28K | 3.84M |
| 2020 | -7.93M | -96K | 29.50M |
| 2021 | -18.54M | -27K | 21.73M |
| 2022 | -20.82M | -7K | 2.99M |
| 2023 | -16.11M | -6K | 848K |
CYCC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 18.34M | 36.55M | 33.40M | 11.88M | 17.50M | 23.91M | 16.52M | 20.44M | 24.18M | 31.14M |
Operating activities | ||||||||||
Net income | -22.55M | -21.19M | -18.88M | -8.44M | -7.83M | -7.28M | -7.47M | -11.79M | -14.34M | -19.38M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 31K | 32K | 43K | 20K | 20K | 29K | 32K | 133K | 210K | 174K |
Stock-based compensation expense | 1.47M | 1.50M | 1.15M | 430K | 466K | 331K | 266K | 782K | 745K | 1.22M |
| Deferred income tax benefit | 1.47M | 1.50M | 1.15M | 430K | 466K | 331K | 266K | 782K | 745K | 1.22M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 296K | 2.57M | 2.90M | 30K | -2.20M | 554K | -1.54M | 370K | -1.46M | 666 |
Cash generated by operating activities | -16.11M | -20.82M | -18.54M | -7.93M | -9.44M | -6.70M | -7.48M | -10.07M | -14.46M | -18.70M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -6K | -7K | -27K | -96K | -10K | -39K | -13K | -3K | -34K | -309K |
Acquisitions Net | 0 | 0 | 0 | 0 | 38K | 0 | 0 | 12K | 0 | 0 |
Cash generated by investing activities | -6K | -7K | -27K | -96K | 28K | -39K | -13K | 9K | 62K | 75K |
Financing activities | ||||||||||
Common Stock Issued | 1.04M | 3.19M | 21.93M | 29.70M | 4.04M | 630K | 14.74M | 6.79M | 11.06M | 0 |
Payments for dividends | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -200K | -201K | -200K |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 848K | 2.99M | 21.73M | 29.50M | 3.84M | 429K | 14.74M | 6.59M | 10.86M | 12.2M |
Net Change In Cash | -14.96M | -18.21M | 3.15M | 21.52M | -5.61M | -6.40M | 7.39M | -3.92M | -3.74M | -6.95M |
Cash at end of period | 3.37M | 18.34M | 36.55M | 33.40M | 11.88M | 17.50M | 23.91M | 16.52M | 20.44M | 24.18M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |